Biocept filed for a $27+ Million offering of stock and warrants on 11/1/19. Biocept provides molecular oncology diagnostics and is based in San Diego, CA. The company trades on NASDAQ under the symbol "BIOC."

The company, develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy." The company's "current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, show progression or be used for monitoring in order to identify specific resistance mechanisms."

The company began offering its liquid biopsy kits containing their ctDNA Target Selector ctDNA technology to laboratories worldwide research use only in January of 2019.

The company intends to use the net proceeds of the offering for general corporate purposes and to fund ongoing operations and expansion of our business. The company's revenue generating efforts are focused on three areas:

• providing laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians who use the biomarker information we provide in order to determine the best treatment plan for their patients
• providing laboratory services utilizing both our CTC and ctDNA testing in order to help pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer; and
• licensing and/or selling our proprietary testing and/or technologies, including our BCTs, to partners in the United States and abroad.

As of this writing the company had a market cap of $16.8 million